PROMISING Alzheimer's Disease (AD) drug solanezumab has failed to meet its main goals in trials, Eli Lilly has announced.
Company shares lost value on the announcement that the drug failed to slow down cognitive decline in patients with Alzheimer's compared to those who took placebo.
Solanezumab targeted beta amyloid, seeking to remove the problematic protein that forms clumps in the brains of Alzheimer's patients, as it had done in mouse studies, in the hope that this would lessen the symptoms and slow the progress of the disease.
The above article was sent to subscribers in Pharmacy Daily's issue from 25 Nov 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Nov 16
